Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Gaku Yamamoto, Yu Tanaka, Yoshitaka Zenke, Jie Liu, Tetsuya Sakai, Hiroki Izumi, Eri Sugiyama, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Susumu S. Kobayashi, Hibiki Udagawa

Cancer Res (2025) 85 (8_Supplement_1): 4714.

https://doi.org/10.1158/1538-7445.AM2025-4714

Published: 21 April 2025

View articletitled, Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Journal Articles

Abstract 7220: Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations

Yuji Shibata, Monique B. Nilsson, Hibiki Udagawa, Jacqulyne P. Robichaux, Junqin He, Xiaoxing Yu, John V. Heymach

Cancer Res (2025) 85 (8_Supplement_1): 7220.

https://doi.org/10.1158/1538-7445.AM2025-7220

Published: 21 April 2025

View articletitled, Abstract 7220: Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations

Journal Articles

Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D

Yu Tanaka, Mirai Tsukuda, Gaku Yamamoto, Eri Sugiyama, Hiroki Izumi, Tetsuya Sakai, Shigeki Umemura, Yoshitaka Zenke, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Hibiki Udagawa

Cancer Res (2025) 85 (8_Supplement_1): 7198.

https://doi.org/10.1158/1538-7445.AM2025-7198

Published: 21 April 2025

View articletitled, Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D

Journal Articles

Abstract 1958: EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs

Tomohiro Takehara, Monique B. Nilsson, Ximeng Liu, Hibiki Udagawa, Naoto Morikawa, Alissa Poteete, Junqin He, Xiaoxing Yu, Thiru Arumugam, Koichi Goto, John V. Heymach

Cancer Res (2024) 84 (6_Supplement): 1958.

https://doi.org/10.1158/1538-7445.AM2024-1958

Published: 22 March 2024

View articletitled, Abstract 1958: EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs

Journal Articles

Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance

Yuji Shibata, Hibiki Udagawa, Monique B. Nilsson, Jacqulyne Robichaux, Ana Galan-Cobo, Marcelo Negrao, David P. Molkentine, Junqin He, Alissa Poteete, Yu Qian, Qian Huang, Ferdinandos Skoulidis, John V. Heymach

Cancer Res (2024) 84 (6_Supplement): 1935.

https://doi.org/10.1158/1538-7445.AM2024-1935

Published: 22 March 2024

View articletitled, Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance

Journal Articles

Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors

Monique B. Nilsson, Alissa Poteete, Hibiki Udagawa, Xiaoxing Yu, Junqin He, Xiuning Le, John Heymach

Cancer Res (2023) 83 (7_Supplement): 383.

https://doi.org/10.1158/1538-7445.AM2023-383

Published: 04 April 2023

View articletitled, Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors

Journal Articles

Abstract 4042: Role of individual HER family members and pan-HER targeting treatment strategy in NRG1 fusion positive cancer

Hibiki Udagawa, Monique Nilsson, Junqin He, Alissa Poteete, John Victor Heymach

Cancer Res (2023) 83 (7_Supplement): 4042.

https://doi.org/10.1158/1538-7445.AM2023-4042

Published: 04 April 2023

View articletitled, Abstract 4042: Role of individual HER family members and pan-HER targeting treatment strategy in NRG1 fusion positive cancer

Journal Articles

Abstract 1026: A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer

Tetsuya Sakai, Yoshitaka Zenke, Mami Onishi, Eri Morita, Masatoshi Yanagida, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Cancer Res (2023) 83 (7_Supplement): 1026.

https://doi.org/10.1158/1538-7445.AM2023-1026

Published: 04 April 2023

View articletitled, Abstract 1026: A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer

Journal Articles

Abstract 5355: Mechanisms of resistance to CLN-081 (TAS6417) in non-small cell lung cancer with EGFR exon 20 insertions

Takuma Hayashida, Yosuke Kagawa, Shunta Mori, Liu jie, Yukie Kashima, Kosuke Tanaka, Hibiki Udagawa, Hiroki Izumi, Susumu Kobayashi

Cancer Res (2022) 82 (12_Supplement): 5355.

https://doi.org/10.1158/1538-7445.AM2022-5355

Published: 15 June 2022

View articletitled, Abstract 5355: Mechanisms of resistance to CLN-081 (TAS6417) in non-small cell lung cancer with EGFR exon 20 insertions

Journal Articles

Abstract 1182: Molecular landscape and ErbB family signaling in NRG fusion NSCLC: Therapeutic implications for pan-ErbB family inhibitors

Hibiki Udagawa, Jacqulyne P. Robichaux, Yasir Y. Elamin, Junqin He, Monique B. Nilsson, John V. Heymach

Cancer Res (2022) 82 (12_Supplement): 1182.

https://doi.org/10.1158/1538-7445.AM2022-1182

Published: 15 June 2022

View articletitled, Abstract 1182: Molecular landscape and ErbB family signaling in NRG fusion NSCLC: Therapeutic implications for pan-ErbB family inhibitors

Journal Articles

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Yukie Kashima, Daisuke Shibahara, Ayako Suzuki, Kyoko Muto, Ikei S. Kobayashi, David Plotnick, Hibiki Udagawa, Hiroki Izumi, Yuji Shibata, Kosuke Tanaka, Masanori Fujii, Akihiro Ohashi, Masahide Seki, Koichi Goto, Katsuya Tsuchihara, Yutaka Suzuki, Susumu S. Kobayashi

Cancer Res (2021) 81 (18): 4835–4848.

https://doi.org/10.1158/0008-5472.CAN-20-2811

Published: 15 September 2021

View articletitled, Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Includes: Supplementary data

Journal Articles

Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation

Tetsuya Sakai, Hibiki Udagawa, Yoshitaka Zenke, Keisuke Kirita, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Genichiro Ishii, Koichi Goto

Cancer Res (2019) 79 (13_Supplement): 4920.

https://doi.org/10.1158/1538-7445.AM2019-4920

Published: 01 July 2019

View articletitled, Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation

Journal Articles

Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC

Jun Sato, Tomoyuki Naito, Hibiki Udagawa, Hidehito Horinouchi, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe, Yoshitaka Zenke, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi, Genichiro Ishii, Koichi Goto

Cancer Res (2019) 79 (13_Supplement): 4919.

https://doi.org/10.1158/1538-7445.AM2019-4919

Published: 01 July 2019

View articletitled, Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC

Journal Articles

Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor

Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi, Naomi Abe, Tomonori Haruma, Toshiharu Komori, Miki Terasaka, Ryoto Fujita, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, Daniel B. Costa, Susumu S. Kobayashi

Cancer Res (2019) 79 (13_Supplement): 1329.

https://doi.org/10.1158/1538-7445.AM2019-1329

Published: 01 July 2019

View articletitled, Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor

Journal Articles

Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Hideki Makinoshima, Shigeki Umemura, Ayako Suzuki, Hiroki Nakanishi, Ami Maruyama, Hibiki Udagawa, Sachiyo Mimaki, Shingo Matsumoto, Seiji Niho, Genichiro Ishii, Masahiro Tsuboi, Atsushi Ochiai, Hiroyasu Esumi, Takehiko Sasaki, Koichi Goto, Katsuya Tsuchihara

Cancer Res (2018) 78 (9): 2179–2190.

https://doi.org/10.1158/0008-5472.CAN-17-2109

Published: 30 April 2018

View articletitled, Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Abstract 7220: Zongertinib demonstrates potent efficacy against cancer cells harboring HER2 non-tyrosine kinase domain mutations

Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D

Abstract 1958: EGFR and mTOR signaling facilitate RET-independent resistance to selective RET-TKIs

Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance

Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors

Abstract 4042: Role of individual HER family members and pan-HER targeting treatment strategy in NRG1 fusion positive cancer

Abstract 1026: A novel detection system of circulating tumor cells based on size-dependent enrichment with immunofluorescent staining of CK8/18 in advanced non-small cell lung cancer

Abstract 5355: Mechanisms of resistance to CLN-081 (TAS6417) in non-small cell lung cancer with EGFR exon 20 insertions

Abstract 1182: Molecular landscape and ErbB family signaling in NRG fusion NSCLC: Therapeutic implications for pan-ErbB family inhibitors

Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation

Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC

Abstract 1329: Preclinical evaluation of TAS6417 as a highly effective, pan-mutation-selective EGFR tyrosine kinase inhibitor

Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only